Eli Lilly & annual free cash flow
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eli Lilly & Free Cash Flow (FCF) History (LLY)
Eli Lilly & reported $8.97B in free cash flow for fiscal 2025, an increase of 138.62% from the previous fiscal year, with a free cash flow margin of 13.77%.
View full Eli Lilly & company overviewEli Lilly & free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.97B | $5.21B | +138.62% | +13.77% |
| 2024 | 2024-12-31 | $3.76B | $2.97B | +374.75% | +8.35% |
| 2023 | 2023-12-31 | $792.0M | −$4.94B | −86.18% | +2.32% |
| 2022 | 2022-12-31 | $5.73B | −$324.7M | −5.36% | +20.08% |
| 2021 | 2021-12-31 | $6.06B | $944.4M | +18.48% | +21.39% |
| 2020 | 2020-12-31 | $5.11B | $1.31B | +34.42% | +20.83% |
| 2019 | 2019-12-31 | $3.80B | −$511.2M | −11.85% | +17.04% |
| 2018 | 2018-12-31 | $4.31B | −$224.9M | −4.96% | +20.07% |
| 2017 | 2017-12-31 | $4.54B | $724.8M | +19.00% | +22.72% |
| 2016 | 2016-12-31 | $3.81B | $1.92B | +100.91% | +17.97% |
| 2015 | 2015-12-31 | $1.90B | −$1.40B | −42.40% | +9.51% |
| 2014 | 2014-12-31 | $3.30B | −$1.43B | −30.22% | +16.80% |
| 2013 | 2013-12-31 | $4.72B | $323.5M | +7.35% | +20.43% |
| 2012 | 2012-12-31 | $4.40B | −$2.16B | −32.96% | +19.46% |
| 2011 | 2011-12-31 | $6.56B | $400.0M | +6.49% | +27.02% |
| 2010 | 2010-12-31 | $6.16B | $2.59B | +72.59% | +26.71% |
| 2009 | 2009-12-31 | $3.57B | −$2.78B | −43.76% | +16.35% |
| 2008 | 2008-12-31 | $6.35B | $2.28B | +55.90% | +31.16% |
| 2007 | 2007-12-31 | $4.07B | — | — | +21.85% |
Eli Lilly & quarterly free cash flow
Q3.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.76B | $6.37B | +458.06% | +33.76% |
| Q1 2026 | 2026-03-31 | $3.01B | $2.85B | +1827.56% | +15.19% |
| Q4 2025 | 2025-12-31 | $677.9M | −$299.8M | −30.66% | +3.51% |
| Q3 2025 | 2025-09-30 | $6.75B | $4.39B | +185.79% | +38.34% |
| Q2 2025 | 2025-06-30 | $1.39B | $1.15B | +475.81% | +8.93% |
| Q1 2025 | 2025-03-31 | $156.0M | −$23.7M | −13.19% | +1.23% |
| Q4 2024 | 2024-12-31 | $977.7M | $2.36B | — | +7.22% |
| Q3 2024 | 2024-09-30 | $2.36B | $1.14B | +93.67% | +20.64% |
| Q2 2024 | 2024-06-30 | $241.4M | $347.7M | — | +2.14% |
| Q1 2024 | 2024-03-31 | $179.7M | −$882.4M | −83.08% | +2.05% |
| Q4 2023 | 2023-12-31 | −$1.38B | −$2.54B | — | −14.79% |
| Q3 2023 | 2023-09-30 | $1.22B | −$380.3M | −23.78% | +12.84% |
| Q2 2023 | 2023-06-30 | −$106.3M | −$918.6M | — | −1.28% |
| Q1 2023 | 2023-03-31 | $1.06B | −$1.10B | −50.77% | +15.26% |
| Q4 2022 | 2022-12-31 | $1.16B | −$808.3M | −41.02% | +15.91% |
| Q3 2022 | 2022-09-30 | $1.60B | $305.0M | +23.56% | +23.04% |
| Q2 2022 | 2022-06-30 | $812.3M | −$581.9M | −41.74% | +12.52% |
| Q1 2022 | 2022-03-31 | $2.16B | $760.5M | +54.43% | +27.63% |
| Q4 2021 | 2021-12-31 | $1.97B | $609.8M | +44.82% | +24.63% |
| Q3 2021 | 2021-09-30 | $1.29B | −$119.0M | −8.42% | +19.11% |
| Q2 2021 | 2021-06-30 | $1.39B | −$819.4M | −37.02% | +20.69% |
| Q1 2021 | 2021-03-31 | $1.40B | $1.27B | +1025.79% | +20.53% |
| Q4 2020 | 2020-12-31 | $1.36B | −$276.7M | −16.90% | +18.29% |
| Q3 2020 | 2020-09-30 | $1.41B | $166.8M | +13.38% | +24.62% |
| Q2 2020 | 2020-06-30 | $2.21B | $1.40B | +172.88% | +40.25% |
| Q1 2020 | 2020-03-31 | $124.1M | $16.5M | +15.33% | +2.12% |
| Q4 2019 | 2019-12-31 | $1.64B | — | — | +26.78% |
| Q3 2019 | 2019-09-30 | $1.25B | — | — | +22.76% |
| Q2 2019 | 2019-06-30 | $811.2M | — | — | +14.39% |
| Q1 2019 | 2019-03-31 | $107.6M | — | — | +2.11% |
| Q4 2014 | 2014-12-31 | $586.5M | −$128.2M | −17.94% | +11.45% |
| Q3 2014 | 2014-09-30 | $1.45B | −$537.2M | −26.97% | +29.83% |
| Q2 2014 | 2014-06-30 | $1.01B | −$629.6M | −38.46% | +20.41% |
| Q1 2014 | 2014-03-31 | $247.3M | −$132.1M | −34.82% | +5.28% |
| Q4 2013 | 2013-12-31 | $714.7M | −$83.9M | −10.51% | +12.30% |
| Q3 2013 | 2013-09-30 | $1.99B | $481.4M | +31.88% | +34.50% |
| Q2 2013 | 2013-06-30 | $1.64B | $365.5M | +28.74% | +27.61% |
| Q1 2013 | 2013-03-31 | $379.4M | −$439.5M | −53.67% | +6.77% |
| Q4 2012 | 2012-12-31 | $798.6M | −$1.08B | −57.49% | +13.41% |
| Q3 2012 | 2012-09-30 | $1.51B | −$390.3M | −20.54% | +27.74% |
| Q2 2012 | 2012-06-30 | $1.27B | −$365.4M | −22.32% | +22.71% |
| Q1 2012 | 2012-03-31 | $818.9M | −$327.6M | −28.57% | +14.62% |
| Q4 2011 | 2011-12-31 | $1.88B | −$74.4M | −3.81% | +31.07% |
| Q3 2011 | 2011-09-30 | $1.90B | $160.4M | +9.22% | +30.91% |
| Q2 2011 | 2011-06-30 | $1.64B | $125.5M | +8.30% | +26.18% |
| Q1 2011 | 2011-03-31 | $1.15B | $188.5M | +19.68% | +19.63% |
| Q4 2010 | 2010-12-31 | $1.95B | — | — | +31.56% |
| Q3 2010 | 2010-09-30 | $1.74B | $434.4M | +33.27% | +30.77% |
| Q2 2010 | 2010-06-30 | $1.51B | — | — | +26.29% |
| Q1 2010 | 2010-03-31 | $958.0M | — | — | +17.46% |
| Q3 2009 | 2009-09-30 | $1.31B | — | — | +23.48% |
Eli Lilly & free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from $5.11B to $8.97B, a compound annual growth rate of 11.91%. Eli Lilly &'s latest reported quarter, Q2 2026, generated $7.76B in free cash flow, an increase of 458.06% year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Eli Lilly & source filings ↗Community posts
Lilly’s obesity combination improves weight loss but raises discontinuation rates
Lilly ($LLY) reported that its experimental EloraTZP combination produced average weight loss of up to 23.3% over 48 weeks in a 367-person study involving overweight or obese adults with type 2 diabetes. The highest-dose combination of elor ...
Lilly seeks eczema label update after hand-and-foot study meets endpoints
Lilly ($LLY) said EBGLYSS achieved clear or almost clear hands and feet in 53% of treated patients after 16 weeks, compared with 27% on placebo, in the randomized ADtouch study. The 221-patient trial included adults and adolescents with mod ...
Lilly wins US approval for once-weekly insulin Onswik
Eli Lilly ($LLY) received FDA approval for Onswik, its once-weekly basal insulin for adults with type 2 diabetes, used alongside diet and exercise. The decision gives the company a less frequently administered alternative to daily basal ins ...
